Create a narrative

EQL Pharma Community

OM:EQL Community

2 Narratives written by author
0 Comments on narratives written by author
27 Fair Values set on narratives written by author

MA

Community Contributor

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.

SEK 86.37

FV

2.9% undervalued

21.49%

Revenue growth p.a.

1

0

17

10 days ago

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

European Market Expansion And Pipeline Development Will Unlock Potential

Key Takeaways Enlarged European market reach and a deep pipeline of generics underpin prospects for robust, sustained revenue and margin growth. Operational efficiencies, disciplined acquisitions, and targeted R&D boost earnings quality and position EQL Pharma for enhanced resilience and market value.

SEK 90.00

FV

6.8% undervalued

28.68%

Revenue growth p.a.

0

0

0

12 days ago